USD 0.25
(-14.21%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 585.72 Million USD | -4.23% |
2022 | 611.56 Million USD | 12.27% |
2021 | 544.7 Million USD | 41.34% |
2020 | 385.39 Million USD | 19.69% |
2019 | 321.99 Million USD | -8.56% |
2018 | 352.12 Million USD | 11.36% |
2017 | 316.2 Million USD | 7.39% |
2016 | 294.44 Million USD | 7.56% |
2015 | 273.74 Million USD | 12.72% |
2014 | 242.85 Million USD | 28.26% |
2013 | 189.34 Million USD | 32.04% |
2012 | 143.4 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 483.57 Million USD | -12.4% |
2024 Q1 | 552.02 Million USD | -5.75% |
2023 Q2 | 575.43 Million USD | 1.41% |
2023 Q4 | 585.72 Million USD | 1.75% |
2023 FY | 585.72 Million USD | -4.23% |
2023 Q1 | 567.42 Million USD | -7.22% |
2023 Q3 | 575.62 Million USD | 0.03% |
2022 Q1 | 567.91 Million USD | 4.26% |
2022 FY | 611.56 Million USD | 12.27% |
2022 Q4 | 611.56 Million USD | 8.71% |
2022 Q3 | 562.56 Million USD | -0.08% |
2022 Q2 | 563.04 Million USD | -0.86% |
2021 Q4 | 544.7 Million USD | 7.77% |
2021 Q2 | 528.76 Million USD | 33.18% |
2021 Q3 | 505.45 Million USD | -4.41% |
2021 FY | 544.7 Million USD | 41.34% |
2021 Q1 | 397.02 Million USD | 3.02% |
2020 Q4 | 385.39 Million USD | 12.99% |
2020 Q1 | 346.74 Million USD | 7.69% |
2020 Q2 | 392.54 Million USD | 13.21% |
2020 Q3 | 341.08 Million USD | -13.11% |
2020 FY | 385.39 Million USD | 19.69% |
2019 FY | 321.99 Million USD | -8.56% |
2019 Q4 | 321.99 Million USD | 14.9% |
2019 Q2 | 266.76 Million USD | -12.22% |
2019 Q1 | 303.9 Million USD | -13.7% |
2019 Q3 | 280.24 Million USD | 5.05% |
2018 Q1 | 348.82 Million USD | 10.32% |
2018 FY | 352.12 Million USD | 11.36% |
2018 Q4 | 352.12 Million USD | -3.54% |
2018 Q3 | 365.05 Million USD | 2.8% |
2018 Q2 | 355.11 Million USD | 1.8% |
2017 Q1 | 290.78 Million USD | -1.24% |
2017 FY | 316.2 Million USD | 7.39% |
2017 Q4 | 316.2 Million USD | 3.97% |
2017 Q3 | 304.12 Million USD | 3.7% |
2017 Q2 | 293.26 Million USD | 0.85% |
2016 Q1 | 266.31 Million USD | -2.72% |
2016 FY | 294.44 Million USD | 7.56% |
2016 Q4 | 294.44 Million USD | 2.03% |
2016 Q3 | 288.59 Million USD | 0.64% |
2016 Q2 | 286.75 Million USD | 7.68% |
2015 Q3 | 262.69 Million USD | -2.17% |
2015 Q1 | 231.65 Million USD | -4.61% |
2015 Q2 | 268.5 Million USD | 15.91% |
2015 FY | 273.74 Million USD | 12.72% |
2015 Q4 | 273.74 Million USD | 4.21% |
2014 Q4 | 242.85 Million USD | 3.46% |
2014 Q3 | 234.73 Million USD | 0.83% |
2014 Q2 | 232.79 Million USD | 21.94% |
2014 Q1 | 190.91 Million USD | 0.83% |
2014 FY | 242.85 Million USD | 28.26% |
2013 Q4 | 189.34 Million USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | 189.34 Million USD | 32.04% |
2012 FY | 143.4 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
uniQure N.V. | 624.01 Million USD | 6.136% |
Agios Pharmaceuticals, Inc. | 126.09 Million USD | -364.499% |
Amicus Therapeutics, Inc. | 617.7 Million USD | 5.177% |
Atara Biotherapeutics, Inc. | 264.73 Million USD | -121.251% |
bluebird bio, Inc. | 424.62 Million USD | -37.94% |
Cara Therapeutics, Inc. | 68.75 Million USD | -751.856% |
Imunon, Inc. | 8.53 Million USD | -6766.339% |
Editas Medicine, Inc. | 150.05 Million USD | -290.34% |
IQVIA Holdings Inc. | 20.56 Billion USD | 97.152% |
Mettler-Toledo International Inc. | 3.5 Billion USD | 83.291% |
Myriad Genetics, Inc. | 312.9 Million USD | -87.193% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 42.542% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -20.159% |
Verastem, Inc. | 71.18 Million USD | -722.825% |
Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.149% |
Waters Corporation | 3.47 Billion USD | 83.152% |
Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.871% |
Biogen Inc. | 12.04 Billion USD | 95.137% |
Nektar Therapeutics | 267.04 Million USD | -119.336% |
Perrigo Company plc | 6.04 Billion USD | 90.304% |
Dynavax Technologies Corporation | 375.02 Million USD | -56.184% |
Illumina, Inc. | 4.36 Billion USD | 86.584% |
Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1565.083% |
Iovance Biotherapeutics, Inc. | 195.73 Million USD | -199.241% |
Heron Therapeutics, Inc. | 256.47 Million USD | -128.373% |
Unity Biotechnology, Inc. | 37.29 Million USD | -1470.653% |
BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 69.01% |
Sangamo Therapeutics, Inc. | 82.43 Million USD | -610.55% |
Evolus, Inc. | 209.68 Million USD | -179.334% |
Adicet Bio, Inc. | 37.12 Million USD | -1477.931% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | -1356.093% |
Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 91.759% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 11.359% |
Agilent Technologies, Inc. | 4.91 Billion USD | 88.09% |
OPKO Health, Inc. | 622.47 Million USD | 5.904% |
Homology Medicines, Inc. | 118.53 Million USD | -394.148% |
Geron Corporation | 146.12 Million USD | -300.835% |
Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 85.539% |
Exelixis, Inc. | 678.44 Million USD | 13.666% |
Viking Therapeutics, Inc. | 20.07 Million USD | -2818.28% |
Anavex Life Sciences Corp. | 12.53 Million USD | -4573.113% |
Intellia Therapeutics, Inc. | 250.8 Million USD | -133.536% |
Zoetis Inc. | 9.29 Billion USD | 93.698% |
Axsome Therapeutics, Inc. | 397.25 Million USD | -47.442% |
Abeona Therapeutics Inc. | 49.17 Million USD | -1091.085% |
Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 88.626% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1109.058% |
Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 77.501% |
Sarepta Therapeutics, Inc. | 2.4 Billion USD | 75.648% |
Corcept Therapeutics Incorporated | 114.81 Million USD | -410.163% |
Halozyme Therapeutics, Inc. | 1.64 Billion USD | 64.49% |
Blueprint Medicines Corporation | 918.64 Million USD | 36.24% |
Insmed Incorporated | 1.66 Billion USD | 64.753% |
TG Therapeutics, Inc. | 169.08 Million USD | -246.41% |
Incyte Corporation | 1.59 Billion USD | 63.214% |
Emergent BioSolutions Inc. | 1.18 Billion USD | 50.596% |